^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BTK degrader

    Related drugs:
    1m
    CaDAnCe-303: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (clinicaltrials.gov)
    P3, N=153, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • bendamustine • catadegbrutinib (BGB-16673)
    2ms
    A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=114, Not yet recruiting, Shanghai Helioson Pharmaceutical Co., Ltd.
    New P1/2 trial • First-in-human
    2ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria (clinicaltrials.gov)
    P1, N=34, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    catadegbrutinib (BGB-16673)
    3ms
    CaDAnCe-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=80, Recruiting, BeOne Medicines
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    4ms
    BGB-16673-102: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (clinicaltrials.gov)
    P1/2, N=146, Recruiting, BeiGene | Trial completion date: Sep 2027 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    4ms
    Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Nurix Therapeutics, Inc.
    New P1/2 trial
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • bexobrutideg (NX-5948)
    4ms
    Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL (clinicaltrials.gov)
    P3, N=620, Not yet recruiting, Nurix Therapeutics, Inc.
    New P3 trial
    |
    Jaypirca (pirtobrutinib) • bexobrutideg (NX-5948)
    4ms
    A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Beqalzi (sonrotoclax) • catadegbrutinib (BGB-16673)
    4ms
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=135, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=225 --> 135
    Enrollment closed • Enrollment change • Adverse events • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101
    5ms
    NX-2127-001: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=248, Recruiting, Nurix Therapeutics, Inc. | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    CD4 (CD4 Molecule)
    |
    zelebrudomide (NX-2127)
    5ms
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=225, Recruiting, AbbVie | N=135 --> 225
    Enrollment change • Adverse events • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101
    5ms
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=135, Recruiting, AbbVie | N=95 --> 135
    Enrollment change • Adverse events • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101